12:00 AM
Feb 22, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LY466700 (Heptazyme): Began Phase I testing

Ribozyme Pharmaceuticals Inc. (RZYM), Boulder, Colo.
Product: LY466700 (Heptazyme)
Business: Infectious diseases
Therapeutic category: Viral replication
Target: HCV RNA
Description: Chemically...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >